

9 February 2026

NOT FOR RELEASE OR DISTRIBUTION IN THE UNITED STATES

## DESPATCH OF RETAIL OFFER BOOKLET

**PERTH, Australia and SAN FRANCISCO, California – 9 February 2026**

PYC Therapeutics Limited (ASX:PYC) (**PYC** or the **Company**) confirms that the retail entitlement offer booklet (**Retail Offer Booklet**) and personalised entitlement and acceptance forms regarding the retail component of the 3 for 5 pro rata accelerated non-renounceable entitlement offer (**Entitlement Offer**), which was announced on Monday 2 February 2026, were despatched to eligible retail shareholders today.

### Commencement of Retail Entitlement Offer

The retail component of the Entitlement Offer (**Retail Entitlement Offer**) opened today, Monday, 9 February 2026 and is expected to close at 5.00pm (AEDT) on Friday, 27 February 2026.

Eligible retail shareholders should carefully read the Retail Offer Booklet for further details about the Retail Entitlement Offer.

### Retail Investor Enquiries

You should seek appropriate professional advice before making any investment decision. If you have any questions in relation to any of the above matters, please contact the PYC's share registry on 1300 288 664 (within Australia) or +61 2 9698 5414 (outside Australia) from 8.30am to 8.30pm (AEDT), Monday to Friday. For other questions, you should consult your broker, solicitor, accountant, financial adviser or other professional adviser.

### About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a clinical-stage biotechnology company creating a new generation of RNA therapies to change the lives of patients with genetic diseases. The Company utilises its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. PYC's drug development programs target monogenic diseases – the indications with the highest likelihood of success in clinical development <sup>1</sup>.

For more information, visit [pyctx.com](https://pyctx.com), or follow us on [LinkedIn](#) and [X](#).

<sup>1</sup> Advancing Human Genetics Research and Drug Discovery through Exome Sequencing of the UK Biobank  
<https://doi.org/10.1101/2020.11.02.2022232>

## Disclaimer

### Not an offer in the United States

*This announcement has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration of the US Securities Act and applicable US state securities laws.*

*This ASX announcement was approved and authorised for release by the Board of PYC Therapeutics Limited*

### CONTACT US

Investor relations and media contact

[investor@pyctx.com](mailto:investor@pyctx.com)

